ELISA: Direct: To detect hBRAK (using 100 μL/well antibody solution) a concentration of0.25 - 1.0 μg/mL of this antibody is required. In conjunction with compatible secondaryreagents, it allows the detection of at least 0.2 - 0.4 ng/well of recombinant hBRAK. Sandwich: To detect hBRAK (using 100 μL/well antibody solution) a concentration of0.25 - 1.0 μg/mL of this antibody is required. This In conjunction with PolyclonalAnti-Human BRAK as a capture antibody, it allows the detection of at least 0.2 - 0.4 ng/wellof recombinant hBRAK. Western blot: To detect hBRAK this antibody can be used at a concentration of0.1 - 0.2 μg/mL. Used in conjunction with compatible secondary reagents the detectionlimit for recombinant hBRAK is 1.5 - 3.0 ng/lane, under either reducing or non-reducingconditions. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Reconstitution
Centrifuge vial prior to opening. Restoree in sterile PBS containing 0.1 % BSA to a concentration of 0.1 - 1.0 mg/mL.
Buffer
PBS, pH 7.2
Handling Advice
Avoid repeated freezing and thawing.
Storage
-20 °C
Storage Comment
Store the lyophilized antibody at -20 °C. Following reconstitution it is stable for two weeks at 2 - 8 °C. Frozen aliquots are stable for 6 months when stored at -20 °C.
BRAK/CXCL14 is a CXC chemokine constitutively expressed at the mRNA level in certain normal tissues but absent from many established tumor cell lines and human cancers. Although multiple investigators have cloned BRAK, little is known regarding the physiologic function of BRAK or the reason for decreased expression in cancer.Synonyms: C-X-C motif chemokine 14, NJAC, SCYB14, Small-inducible cytokine B14